To promote its once-daily medication designed to address migraine headaches and seizures, Upsher-Smith Laboratories recently launched its redesigned website for Qudexy XR (topiramate) extended-release capsules — along with a branded program allowing better product accessibility.
Upsher-Smith’s online Access Pathways Program accompanies an educational video, a how-to guide and patient enrollment form accessible through the website.
Patients who sign up for Access Pathways may be eligible for zero co-pays or alternatively low-cost choices. Additionally, participating consumers can confirm their benefits and authorizations; and obtain assistance with stocking.
“Upsher-Smith understands that access and affordability for extended-release brand products can be a challenge for patients and an administrative hurdle for physician offices,” Upsher-Smith President and CEO Rusty Field said. “The updated website offers resources that will provide eligible patients co-pay assistance and administrative support to practitioners that will allow them to prescribe Qudexy XR with greater ease.”
Previously indicated as sole or adjunctive therapy for epileptic seizures, Qudexy XR can now be prescribed to treat migraine in individuals ages 12 and up, officials said. It is contraindicated in the case of pregnancy; possible side effects may include dizziness or nausea.
Based in Maple Grove, Minnesota, Upsher-Smith has delivered medications for almost a century.